Skip to content
StockMarketAgent

BMY vs MRK: side-by-side analysis

Cross-read of BMY (Bristol-Myers Squibb Company) versus MRK (Merck & Co. Inc.): BMY looks meaningfully undervalued at $56.2 versus a fair-value midpoint of $84.5, while MRK appears in our peer table at a forward P/E of 11.6x and ROE of 18.9%. Our current rating for BMY is Strong Buy.

Where BMY and MRK sit on fair value

BMY's composite fair-value range is $68.8–$101 (midpoint $84.5), versus a current price of $56.2. MRK is one of BMY's closest sector neighbours and shows up directly in the peer table inside our full report, with a market-cap of $275.1B, P/E of 11.6x, EV/EBITDA of 10.8x, and an operating margin of 38.6%. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.

Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between BMY and MRK is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.

Where they actually differ

BMY is classified as a turnaround stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. MRK, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 9.1× forward P/E with a PEG of 178.00 is not the same on BMY as it is on MRK unless they share the same growth profile, capital intensity, and moat half-life.

BMY's moat assessment is 6.5/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against MRK should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.

Which one wins on each dimension

Valuation: BMY looks meaningfully undervalued versus our fair-value midpoint. The full report's peer table compares BMY and MRK directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for BMY is bound by the kill-scenarios list in Section 2; the equivalent for MRK would need its own report. We do not co-rate two companies on a single page.

Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether BMY or MRK is the better expression of the same theme.

Bottom line — BMY or MRK?

Our rating for BMY is Strong Buy with a 80/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes MRK. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.

For the full evidence on BMY, including the explicit peer multiples versus MRK and the rest of the comp set, see the canonical report at /stocks/bmy/analysis. For MRK's standalone report, see /stocks/mrk/analysis.

Frequently asked questions

BMY vs MRK: which is cheaper today?

BMY looks meaningfully undervalued at $56.2 versus a fair-value midpoint of $84.5 (range $68.8–$101). The peer table inside the full report compares BMY and MRK directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.

Is BMY a better buy than MRK?

Our current rating for BMY is Strong Buy; we do not co-rate MRK on this page — see MRK's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.

What archetype is BMY?

Bristol-Myers Squibb Company is classified as a turnaround stock, which determines our deceleration curve, terminal multiple, and probability weights. MRK's own archetype is in its own report.

What is BMY's moat score versus MRK?

BMY's moat score is 6.5/10. The full moat section covers source, durability, and threat timeline; MRK's moat assessment is in its own standalone report.

Research for educational purposes. Not personalised investment advice. See the full BMY report for the canonical evidence.